» Articles » PMID: 27791178

Structural Basis of Recognition of Farnesylated and Methylated KRAS4b by PDEδ

Abstract

Farnesylation and carboxymethylation of KRAS4b (Kirsten rat sarcoma isoform 4b) are essential for its interaction with the plasma membrane where KRAS-mediated signaling events occur. Phosphodiesterase-δ (PDEδ) binds to KRAS4b and plays an important role in targeting it to cellular membranes. We solved structures of human farnesylated-methylated KRAS4b in complex with PDEδ in two different crystal forms. In these structures, the interaction is driven by the C-terminal amino acids together with the farnesylated and methylated C185 of KRAS4b that binds tightly in the central hydrophobic pocket present in PDEδ. In crystal form II, we see the full-length structure of farnesylated-methylated KRAS4b, including the hypervariable region. Crystal form I reveals structural details of farnesylated-methylated KRAS4b binding to PDEδ, and crystal form II suggests the potential binding mode of geranylgeranylated-methylated KRAS4b to PDEδ. We identified a 5-aa-long sequence motif (Lys-Ser-Lys-Thr-Lys) in KRAS4b that may enable PDEδ to bind both forms of prenylated KRAS4b. Structure and sequence analysis of various prenylated proteins that have been previously tested for binding to PDEδ provides a rationale for why some prenylated proteins, such as KRAS4a, RalA, RalB, and Rac1, do not bind to PDEδ. Comparison of all four available structures of PDEδ complexed with various prenylated proteins/peptides shows the presence of additional interactions due to a larger protein-protein interaction interface in KRAS4b-PDEδ complex. This interface might be exploited for designing an inhibitor with minimal off-target effects.

Citing Articles

Targeting KRAS: from metabolic regulation to cancer treatment.

Shi Y, Zheng H, Wang T, Zhou S, Zhao S, Li M Mol Cancer. 2025; 24(1):9.

PMID: 39799325 PMC: 11724471. DOI: 10.1186/s12943-024-02216-3.


Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.

Kwon J, Dilly J, Liu S, Kim E, Bian Y, Dharmaiah S bioRxiv. 2024; .

PMID: 39484452 PMC: 11526993. DOI: 10.1101/2024.10.22.618529.


KRas4b-Calmodulin Interaction with Membrane Surfaces: Role of Headgroup, Acyl Chain, and Electrostatics.

Shree S, McLean M, Stephen A, Sligar S Biochemistry. 2024; 63(21):2740-2749.

PMID: 39382513 PMC: 11760336. DOI: 10.1021/acs.biochem.4c00116.


KRAS-Driven Tumorigenesis and KRAS-Driven Therapy in Pancreatic Adenocarcinoma.

Than M, OHara M, Stanger B, Reiss K Mol Cancer Ther. 2024; 23(10):1378-1388.

PMID: 39118358 PMC: 11444872. DOI: 10.1158/1535-7163.MCT-23-0519.


Differential Lipid Binding Specificities of RAP1A and RAP1B are Encoded by the Amino Acid Sequence of the Membrane Anchors.

Araya M, Chen W, Ke Y, Zhou Y, Gorfe A, Hancock J J Am Chem Soc. 2024; 146(29):19782-19791.

PMID: 39001846 PMC: 11276784. DOI: 10.1021/jacs.4c02183.


References
1.
Reid T, Terry K, Casey P, Beese L . Crystallographic analysis of CaaX prenyltransferases complexed with substrates defines rules of protein substrate selectivity. J Mol Biol. 2004; 343(2):417-33. DOI: 10.1016/j.jmb.2004.08.056. View

2.
Forbes S, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H . COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2014; 43(Database issue):D805-11. PMC: 4383913. DOI: 10.1093/nar/gku1075. View

3.
Zhao H, Ghirlando R, Piszczek G, Curth U, Brautigam C, Schuck P . Recorded scan times can limit the accuracy of sedimentation coefficients in analytical ultracentrifugation. Anal Biochem. 2013; 437(1):104-8. PMC: 3676908. DOI: 10.1016/j.ab.2013.02.011. View

4.
Roy M, Leventis R, Silvius J . Mutational and biochemical analysis of plasma membrane targeting mediated by the farnesylated, polybasic carboxy terminus of K-ras4B. Biochemistry. 2000; 39(28):8298-307. DOI: 10.1021/bi000512q. View

5.
Prior I, Lewis P, Mattos C . A comprehensive survey of Ras mutations in cancer. Cancer Res. 2012; 72(10):2457-67. PMC: 3354961. DOI: 10.1158/0008-5472.CAN-11-2612. View